Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 619-627

  Seto, Takashi ^a   Esaki, Taito ^a   Hirai, Fumihiko ^a   Arita, Shuji ^a   Nosaki, Kaname ^a   Makiyama, Akitaka ^a   Kometani, Takuro ^a   Fujimoto, Chinatsu ^a   Hamatake, Motoharu ^a   Takeoka, Hiroaki ^a   Agbo, Felix ^b   Shi, Xiaojin ^b  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

AZD7762; Chk1; Japanese; Phase I; Safety; Solid tumours

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BRADYCARDIA; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; JAPANESE; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SOLID TUMOR; STOMATITIS; T WAVE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; THIOPHENES; UREA;

EID: 84883487392     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2234-6     Document Type: Article

References (19)

1. Bucher N, Britten CD (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98:523-528
2. Ashwell S, Zabludoff S (2008) DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14:4032-4037
3. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-383
4. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff Z, Cook JA (2010) In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 16:2076-2084
5. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, Rosenberg S, Fesik S, Zhang H (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2:543-548
6. Janetka JW, Ashwell S, Zabludoff S, Lyne P (2007) Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 10:473-486
7. Morgan MA, Parsels LA, Maybaum J, Lawrence TS (2008) Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 14:6744-6750
8. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966
9. Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G (2011) Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 29(15S):abst 3033
10. Sausville EA, LoRusso P, Carducci MA, Barker PN, Agbo F, Oakes P, Senderowicz AM (2011) Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 29(15S):abst 3058
11. AstraZeneca (2011) Global policy: bioethics. Available at: http://www.astrazeneca.com/Responsibility/Code-policies-standards/ Our-global-policies
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, Ikeda K, Nakayama K, Nakanishi M, Nakayama K (2000) Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 14:1439-1447
14. Erickson JR, He BJ, Grumbach IM, Anderson ME (2011) CaMKII in the cardiovascular system: sensing redox states. Physiol Rev 91:889-915
15. +-ATPase is critical for skeletal and heart muscle function in zebrafish. J Cell Sci. doi: 10.1242/jcs.115808 [Epub ahead of print]
16. Aapro MS, Martin C, Hatty S (1998) Gemcitabine - a safety review. Anticancer Drugs 9:191-201
17. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755-762
18. Takao S, Tokuda Y, Saeki T, Funai J, Ishii M, Takashima S (2012) Long-term gemcitabine administration in heavily pretreated Japanese patients with metastatic breast cancer: additional safety analysis of a phase II study. Breast Cancer 19:335-342
19. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908-915